Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Anti-mycolic acid gallibodies as labelling tools in tuberculosis-related biological samples
Dissertation (MSc (Biochemistry))--University of Pretoria, 2019.
Saved in:
| Other Authors: | |
|---|---|
| Format: | Thesis |
| Language: | English |
| Published: |
University of Pretoria
2024
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1867613535486345216 |
|---|---|
| access_status_str | Open Access |
| author2 | Verschoor, Jan Adrianus |
| author_browse | Verschoor, Jan Adrianus |
| author_facet | Verschoor, Jan Adrianus |
| collection | Thesis |
| dc_rights_str_mv | © 2021 University of Pretoria. All rights reserved. The copyright in this work vests in the University of Pretoria. No part of this work may be reproduced or transmitted in any form or by any means, without the prior written permission of the University of Pretoria. |
| description | Dissertation (MSc (Biochemistry))--University of Pretoria, 2019. |
| format | Thesis |
| id | oai:repository.up.ac.za:2263/97862 |
| institution | University of Pretoria (South Africa) |
| language | English |
| last_indexed | 2026-06-10T12:37:41.590Z |
| license_str | Other — see source repository |
| provenance_str_mv | Harvested via OAI-PMH from UPSpace — University of Pretoria Institutional Repository |
| publishDate | 2024 |
| publishDateRange | 2024 |
| publishDateSort | 2024 |
| publisher | University of Pretoria |
| publisherStr | University of Pretoria |
| record_format | dspace |
| source_str | UPSpace — University of Pretoria Institutional Repository |
| spelling | oai:repository.up.ac.za:2263/97862 Anti-mycolic acid gallibodies as labelling tools in tuberculosis-related biological samples Verschoor, Jan Adrianus jmolatseli@gmail.com Stoltz, Anton Carel Lemmer, Yolandy Molatseli, Mosa Jennifer UCTD Dissertation (MSc (Biochemistry))--University of Pretoria, 2019. Tuberculosis (TB) is a curable infectious disease, but remains a persistent scourge of mankind. It is caused by Mycobacterium tuberculosis (M. tb) that is a master of survival in the human host, where it can lie dormant for decades, build up resistance to antibiotics and await conditions for relapsing into active disease. It demands a global strategy to manage the epidemic, of which the single most important element is fast and affordable accurate diagnosis. To date, the only reliable diagnosis of active disease depends on sputum samples, which consequently leads to misdiagnosis of extrapulmonary TB, paediatric TB and TB in immune compromised populations such as HIV infected individuals. Because of this, the World Health Organization (WHO) and Foundation for Innovative New Diagnostics (FIND) called for a non-sputum-based triage test for the diagnosis of active tuberculosis (TB) with specific target product profiles (TPP) to eradicate TB by 2035. Our TB research group is focused on the development of TB diagnostics based on the detection of surrogate marker anti-mycolic acids (anti-MA) antibodies in patient blood samples at the point of care level. Mycolic acids (MA) are cell wall waxes from the mycobacterial infectious agent. The group has created recombinant monoclonal antibodies against MA, selected from a semi-synthetic chicken phage displayed antibody gene library, which was found to have inadequate avidity for application in sensitive TB diagnosis. In this study, attempts were made to increase avidity of the recombinant antibodies by creation of oligomers of their antigen binding short chain variable (scFv) fragments. Two strategies were applied to this end: first, shortening the synthetic linker between the heavy and light variable domains of the anti-MA scFv’s and second, fusing the scFv genes with the core streptavidin gene that can be expressed to generate spontaneous non-covalent tetramers. Both approaches yielded oligomeric antigen binding proteins with significantly improved avidity for MA binding compared to that of scFv. The best of these were selected to demonstrate their utility in an originally designed lateral flow immunoassay, which opens the way for its further development into that much needed diagnostic device for point of care screening for active TB in disease burdened communities and health centres. Biochemistry MSc (Biochemistry) Unrestricted Faculty of Natural and Agricultural Sciences 2024-08-26T12:34:13Z 2024-08-26T12:34:13Z 2020-04 2019-11 Dissertation * A2020 http://hdl.handle.net/2263/97862 en © 2021 University of Pretoria. All rights reserved. The copyright in this work vests in the University of Pretoria. No part of this work may be reproduced or transmitted in any form or by any means, without the prior written permission of the University of Pretoria. application/pdf University of Pretoria |
| spellingShingle | UCTD Anti-mycolic acid gallibodies as labelling tools in tuberculosis-related biological samples |
| title | Anti-mycolic acid gallibodies as labelling tools in tuberculosis-related biological samples |
| title_full | Anti-mycolic acid gallibodies as labelling tools in tuberculosis-related biological samples |
| title_fullStr | Anti-mycolic acid gallibodies as labelling tools in tuberculosis-related biological samples |
| title_full_unstemmed | Anti-mycolic acid gallibodies as labelling tools in tuberculosis-related biological samples |
| title_short | Anti-mycolic acid gallibodies as labelling tools in tuberculosis-related biological samples |
| title_sort | anti mycolic acid gallibodies as labelling tools in tuberculosis related biological samples |
| topic | UCTD |
| url | http://hdl.handle.net/2263/97862 |